SCHEMBL214851

SCHEMBL214851

Cc1ccc(N(C(=O)c2nc[nH]c2C(N)=O)c2ccc3[nH]cnc3c2)c(C)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.33
KDM4E B2RXH2 3/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 2/20 0.33
PARP1 P09874 2/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
PAX8 Q06710 2/20 0.33
QPCT Q16769 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MMP9 P14780 1/20 0.33
CHEK1 O14757 1/20 0.33
PIM1 P11309 1/20 0.33
RPS6KA3 P51812 1/20 0.33
MAPT P10636 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL217227 0.78 POLB (0.37) SMN1; SMN2KDM4ELMNAALDH1A1TDP1
SCHEMBL215550 0.78 MAP2 (0.34) SMN1; SMN2KDM4ELMNAMAPTMEN1
SCHEMBL213207 0.77 LMNA (0.48) SMN1; SMN2KDM4ELMNATSHRALDH1A1
SCHEMBL216235 0.74 KDM4E (0.38) KDM4ETSHRALDH1A1TDP1MAPT
SCHEMBL214350 0.73 PAX8 (0.36) SMN1; SMN2KDM4ELMNATSHRALDH1A1
SCHEMBL213623 0.72 MAP2 (0.36) SMN1; SMN2KDM4ETDP1CHEK1NPC1
SCHEMBL214152 0.71 ALDH1A1 (0.38) SMN1; SMN2KDM4ETSHRALDH1A1MAPT
SCHEMBL216492 0.70 POLB (0.37) SMN1; SMN2KDM4ELMNAALDH1A1TDP1
SCHEMBL214403 0.70 ALDH1A1 (0.42) SMN1; SMN2KDM4EALDH1A1TDP1MEN1
SCHEMBL216070 0.69 POLB (0.47) SMN1; SMN2KDM4ELMNAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 SMN1; SMN2 2516/4885KDM4E 952/4885LMNA 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.